Novel Molecular and Nano Biosensor Approaches for Comprehensive Thalassemia Detection

Thalassemia, a genetic hematologic disorder, is a huge global public health concern, impacting about 360 million carriers globally. The disease is notably prevalent in the Middle East, Southeast Asia, and certain African and Asian countries. The most severe form, β-thalassemia major, requires regular blood transfusions for survival. The costly nature of treatment poses a considerable hardship, especially in developing nations. The condition also has a considerable influence on the emotional well-being of affected persons, particularly youngsters. A range of novel approaches have been presented for the detection and management of thalassemia. Recent advances in nanotechnology have involved the utilization of nanomaterials in colorimetric assays, the integration of nanopore sequencing with bioinformatics analysis, the assessment of cell-free fetal DNA through digital PCR for non-invasive prenatal screening, the application of electrochemical biosensors, and the implementation of diverse automated detection systems. The ideas, recommendations, and practical implementations of these new technologies are completely evaluated, revealing their capacity to enhance precision, sensitivity, and early detection in contrast to present techniques. Key features are user-friendly operation, cost-effectiveness, quantitative evaluative capabilities, and adaptability for quick implementation. Yet difficulties remain about scale, lack of resources, and incorporation into therapeutic environments. Survey broadens to emergent fields such as artificial intelligence to promote better data analysis and careful variation analysis. These novel advancements indicate tremendous potential in enhancing thalassemia screening approaches, facilitating rapid cures, and decreasing the global disease burden. The ongoing research efforts aiming at developing and validating these approaches have the potential to bring about considerable progress in the diagnosis and treatment of thalassemia on a worldwide basis.